Take a trial of UK to unlock this pageFind out more
© Stockopedia 29th May, 2017

AstraZeneca

AZN 5227p 18.0  0.3%
26/05/17 0.500k

Momentum
Relative Strength (%)
1m
3m
1yr
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
vs.
market
vs.
industry
Growth & Value
Margin of Safety (beta)
Screens Passed 2
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2011 2012 2013 2014 2015 2016 TTM 2017E 2018E CAGR / Avg
Revenue $m
Operating Profit $m
Net Profit $m
EPS Reported $
EPS Normalised $
EPS Growth %
PE Ratio x
PEG x
Profitability
Operating Margin %
ROA %
ROCE %
ROE %
Cashflow
Op. Cashflow ps $
Capex ps $
Free Cashflow ps $
Last ex-div: 10th Aug, paid: 11th Sep more... Dividends
Dividend ps $
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc $m
Working Capital $m
Net Fixed Assets $m
Net Debt $m
Book Value $m
Average Shares m
Book Value ps $ -8.2%

FINANCIAL BRIEF: For the three months ended 31 March 2017, AstraZeneca plc revenues decreased 12% to $5.41B. Net income decreased 17% to $537M. Revenues reflect United States segment decrease of 34% to $1.49B, Western Europe segment decrease of 7% to $1.13B. Net income also reflects Other operating income exp Restructurin increase from $0K to $76M (expense), Restructuring Charges/Provisions increase from $38M to $104M (expense). more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score
B+
B+
Other Ratios
Leverage (ttm) Total -Intang +Pension
Gross Gearing %
Net Gearing %
Cash / Assets %
vs.
market
vs.
industry
Recent History
Latest interim period (ended 31st Mar '17) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2017
31st Dec 2018

Price Target: $66.1
(-2.21% below Price)
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: +5.7% ($) ($) ($) ($) ($) ($)
Consensus Estimate
1m Change
3m Change
35 brokers Broker Consensus Trend
Broker Recommendations for AstraZeneca
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 0 5 12 9 8

Named Brokers and Analysts
Credit Suisse Matthew Weston , Piper Jaffray Richard Purkiss , SEB Equities Richard Koch , Leerink Partners LLC Seamus Fernandez , BERNSTEIN Tim Anderson , Investec Bank (UK) Plc Andrew Whitney , Danske Markets Lars Hevreng , Natixis Jean-Jacques Le Fur , Swedbank Markets Johan Unnerus , Nordea Markets Michael Novod , Societe Generale Justin Smith , Pareto Securities AS Finlay Heppenstall , Berenberg Alistair Campbell , Oddo Securities Pierre Corby , Shore Capital Stockbrokers Tara Raveendran , Bryan Garnier Eric Le Berrigaud , Morningstar, Inc. Damien Conover , Day by Day Valérie GASTALDY , Landesbank Baden-Wuerttemberg Timo Kuerschner , Liberum Naresh Chouhan , Cantor Fitzgerald Europe Brian White , Baader Helvea Equity Research Odile Rundquist , Beaufort Securities Ben Maitland , Foveal Amit Roy ,

Profile Summary

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.

Directors: Pascal Soriot (CEO) 57, Marc Dunoyer (CFO) 64, Fiona Cicconi (EVP) , Sean Bohen (EVP) , Pam Cheng (EVP) 45, Ruud Dobber (EVP) , Bahija Jallal (EVP) , Mark Mallon (EVP) , Menelas Pangalos (EVP) , Leon Wang (EVP) , Leif Johansson (NEC) 66, Philip Broadley (DRC) 53, Marcus Wallenberg (NED) 61, Genevieve Berger (NID) 62, Bruce Burlington (NID) 68,

No. of Employees: 59,700 No. of Shareholders: 90,113


Last Annual December 31st, 2016
Last Interim March 31st, 2017
Incorporated June 17, 1992
Public Since September 21, 2007
Shares in Issue 1,265,640,640
Free Float 1.26bn (99.6%)

AZN Share Price Performance AZNQuote
5227p
18.0  0.3%
Traded 5:06pm · Minimum 15 min delayed · NMS: 0.500k

Latest AZN News Announcements (delayed)

Upcoming AZN Events
Monday 5th June, 2017
AstraZeneca PLC Investor Science Event at ASCO 2017
Friday 9th June, 2017
AstraZeneca PLC at Bryan Garnier Oncology Day
Friday 9th June, 2017
AstraZeneca PLC at Jefferies Healthcare Conference
Tuesday 13th June, 2017
AstraZeneca PLC at Goldman Sachs Group Investor Conference
Wednesday 14th June, 2017
AstraZeneca PLC at Barclays European Select Conference
Thursday 27th July, 2017
Q2 2017 AstraZeneca PLC Earnings Release
Thursday 9th November, 2017
Q3 2017 AstraZeneca PLC Earnings Release

Recent ↓
Wednesday 10th May, 2017
AstraZeneca PLC Investor Roadshow - Chicago
Tuesday 9th May, 2017
AstraZeneca PLC at Redburn European Equity Conference
Wednesday 3rd May, 2017
AstraZeneca PLC at Deutsche Bank Health Care Conference
Thursday 27th April, 2017
AstraZeneca PLC Annual Shareholders Meeting
Thursday 27th April, 2017
Q1 2017 AstraZeneca PLC Earnings Call
Thursday 27th April, 2017
Q1 2017 AstraZeneca PLC Earnings Media Conference
Thursday 27th April, 2017
Q1 2017 AstraZeneca PLC Earnings Release
Wednesday 22nd March, 2017
AstraZeneca PLC at Berenberg Equities Seminar
Tuesday 14th March, 2017
AstraZeneca PLC at Barclays Global Healthcare Conference
Thursday 16th March, 2017
AstraZeneca PLC at Goldman Sachs European Corporate Conference
Monday 13th March, 2017
AstraZeneca PLC at Exane BNP Healthcare Conference
Monday 6th March, 2017
AstraZeneca PLC at Cowen Health Care Conference
Thursday 2nd March, 2017
AstraZeneca PLC at Daiwa/Bernstein Investment Conference Tokyo
Tuesday 28th February, 2017
AstraZeneca PLC at Credit Suisse Global Healthcare Conference
Thursday 16th February, 2017
Dividend For AZN
Wednesday 15th February, 2017
Dividend For AZN
Wednesday 15th February, 2017
Dividend For AZN
Monday 6th February, 2017
AstraZeneca PLC Investor Roadshow - Europe and North America
Thursday 2nd February, 2017
Full Year 2016 AstraZeneca PLC Earnings Call
Thursday 2nd February, 2017
Full Year 2016 AstraZeneca PLC Earnings Media Conference


Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2017.


Should you buy AZN

Access AZN Analytics Now!

FREE TRIAL or TAKE THE TOUR
Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis